ITEMS OF INTEREST TO THE IMAGING RESEARCH COMMUNITY:
- The NCI home page (http://www.cancer.gov/) has been updated. Your comments and suggestions are invited, please send them to email@example.com
- UPCOMING NIH REGIONAL SEMINAR ON PROGRAM FUNDING AND GRANTS ADMINISTRATION ON JUNE 1 AND 2, 2000 (NOT-OD-00-027)
A regional seminar covering topics related to the National Institutes of Health extramural program funding and grants administration has been scheduled for Thursday and Friday, June 1 and 2, in Kansas City, Missouri.
- NATIONAL INSTITUTES OF HEALTH LAUNCHES "CLINICALTRIALS.GOV"
The National Institutes of Health has announced the launch of the first phase of a consumer- friendly database, "ClinicalTrials.gov", with information on more than 4,000 federal and private medical studies involving patients and others at more than 47,000 locations nationwide. The new database may be reached at http://clinicaltrials.gov/.
"ClinicalTrials.gov" may also be reached through the National Library of Medicine's Web site at http://www.nlm.nih.gov and through its consumer health information service, MEDLINE"plus" at http://medlineplus.gov. MEDLINE"plus" has extensive links to information about 350 diseases and health conditions, much of it from the NIH Institutes and Centers
- TRANS-NIH SCIENTIFIC INITIATIVES PAGE
- MODULAR GRANTS INFORMATION
The FAQ section of Modular Grant application website describes the budget development process. It specifically indicates that future year escalation costs are to be included in the development of modular budgets. The website also includes the guidance prepared for reviewers. It will be distributed to reviewers, again, in advance of the next review meetings.
- NIH: DISTRIBUTING PA TEXT TO REVIEWERS
A working group of trans-NIH representation was formed to reconsider the policy of distributing the PA text to reviewers. Concerns were related to whether emphasis on a given PA might sway the study section toward a favorable review of one program or application vs. another and the volume of paper sent to reviewers. The workgroup recommended that the practice of sending PAs be discontinued for R01 applications. It is recommended that a list of the NIH web site URLs for the PAs be sent to the reviewers. For any unusual PAs, CSR will continue to send copies to the reviewers. SRAs are responsible for calling the reviewers' attention to specific criteria that need to be considered in the review of each mechanism.
As a practical note for applicants, special notice can be drawn to the PA being responded to in the text of the application.
- POLICY OF THE NATIONAL CANCER INSTITUTE FOR ALLOWABLE REQUESTED BUDGET LEVELS OF COMPETING CONTINUATION (TYPE 2) PROGRAM PROJECT (P01) GRANT APPLICATIONS (NOTICE: CA-00-010)
To align more closely budgetary increases for P01 program project awards with overall NCI budget growth, beginning with the June 1, 2000 receipt date, budget requests for direct costs for NCI supported competing continuation (type 2) Program Project (P01) grant applications must not exceed an increase of 20% over the direct costs to be awarded in the last non-competing (Type 5) year. Subsequent future year budget requests of competing continuations cannot, over the life of the proposed project, exceed simple inflationary adjustments. This dollar total is exclusive of sub-contractual Facilities and Administrative (F&A) costs that appear as a direct cost in the budget of the applicant organization.
- MOLECULAR TARGET DRUG DISCOVERY FOR CANCER: COMPETING SUPPLEMENTS(RFP#PAR-00-062)
Letter of Intent Receipt Date: June 6, 2000; Application Receipt Date: July 18, 2000 Among the priorities of the 2001 Bypass Budget was to identify and use molecular targets for the discovery and clinical testing of new anticancer agents based on the molecular mechanisms that underlie neoplastic transformations, cancer growth and metastasis. NCI invites competitive supplement applications for existing NIH grants to exploit molecular targets for drug discovery.
- NIMH EXPLORATORY/DEVELOPMENTAL GRANT (R21) PROGRAM (PA-00-073)
The Division of Neuroscience and Basic Behavioral Science and the Division of Services and Intervention Research of the National Institute of Mental Health (NIMH) invites applications for Exploratory/Developmental Grants (R21) that fall within their research interests. The objective of this Exploratory/Developmental Grant (R21) mechanism is to encourage applications for one-time grants.
- HIGH IMPACT RESEARCH: FEASIBILITY STUDIES (PAR-00-075) (NIDCD)
Application Receipt Date: July 21, 2000
The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for feasibility studies of high impact (HI) research focused on hearing, balance, smell, taste, voice, speech, and language, the scientific mission areas of the NIDCD. This Program Announcement (PA) supersedes a previous NIDCD PA: High Impact Research: Feasibility
- MULTIDISCIPLINARY CLINICAL RESEARCH CENTERS FOR ARTHRITIS, MUSCULOSKELETAL, AND SKIN DISEASES (AR-00-004) (NIAMS)
Letter of Intent Receipt Date: December 1, 2000; Application Receipt Date: January 17, 2001
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications for a new program of Multidisciplinary Clinical Research Centers (MCRCs) in arthritis and/or musculoskeletal disorders and/or skin diseases.
- ADDENDUM - CANCER EDUCATION GRANT PROGRAM (PAR-00-033) (NOT-CA-00-012)
- MENTORED RESEARCH SCIENTIST DEVELOPMENT AWARD (K01) (NOT-RR-00-005)
- INSTITUTIONAL CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT (PAR-00-063)- NCI
Letter of Intent Receipt Date: May 1 every year; Application Receipt Date: June 1 every year
The purpose of the National Cancer Institute (NCI) Institutional Clinical Oncology Career Development Program is to increase the number of medical doctors (M.D.'s, D.O.'s) and doctorally degreed Oncology Registered Nurses who are motivated and properly trained to: (1) communicate and collaborate with basic/behavioral research scientists in order to expedite the translation of basic/ behavioral research information into patient-oriented cancer research; (2) perform independent clinical oncology research that develops and tests rational scientific hypotheses based on fundamental and clinical research findings with the potential for improving the medical care of cancer patients; and (3) design and test innovative clinical protocols and manage all phases (i.e., pilot/Phase I, Phase II, and Phase III) of clinical trials research.
- PARTICIPATION OF THE NATIONAL CANCER INSTITUTE IN THE NIH MENTORED QUANTITATIVE RESEARCH CAREER DEVELOPMENT AWARD (NOT-CA-00-014)
The National Cancer Institute originally was not a participant in the Program Announcement (PA), number PA-99-087, published in the NIH Guide on April 13, 1999 for the Mentored Quantitative Research Career Development Award using the K25 grant mechanism. The NCI wishes to inform the applicants that it will participate in this PA for all future grant application receipt deadlines beginning with the June 1, 2000 deadline.
- THE NCI SCHOLARS PROGRAM (RFA-CA-01-007)
Letter of Intent Receipt Date: May 8, 2000; Application Receipt Date: June 12, 2000
The purpose of the NCI Scholars Program is to provide an opportunity for outstanding new investigators to begin their independent research careers first within the special environment on the intramural campuses of the National Cancer Institute (NCI) and second to continue their careers at an institution of their choice. This is accomplished by providing, through an NCI intramural funding mechanism for up to four years, the necessary resources to initiate an independent research program at the NCI, followed by support for two years through an extramural funding mechanism (K22) of their research program at the extramural institution to which they are recruited.
- INITIATIVE FOR MINORITY STUDENTS: BRIDGES TO THE BACCALAUREATE (GM-00-001) - NIGMS
Letter of Intent Receipt Date: June 1, 2000; Application Receipt Date: July 17, 2000
The National Institute of General Medical Sciences (NIGMS) and the Office of Research on Minority Health (ORMH), National Institutes of Health (NIH), reannounce opportunities to apply for funding for the Bridges to the Future Program.
OTHER GOVERNMENT AGENCIES
- DEPARTMENT OF ENERGY Office of Science Financial Assistance Program Notice 00-13; Medical Applications Program
Preapplications due by April 14, 2000; Formal applications: May 30, 2000
The Office of Biological and Environmental Research (OBER) of the Office of Science (SC), U.S. Department of Energy (DOE), hereby announces its interest in receiving grant applications to support one specific research area within the Medical Applications Program: Imaging Gene Expression in Health and Disease. The specific goals include development of nuclear medicine driven technologies to image mRNA transcripts in real time in tissue culture and whole animals.
- BIOPHOTONICS PARTNERSHIP INITIATIVE (NSF 00-54)- NSF DEADLINE DATE: MAY 15, 2000
The Engineering Directorate of the National Science Foundation (NSF) announces a Biophotonics Partnership initiative seeking high risk/high return, multidisciplinary studies of novel concepts in biophotonics. NIH and DARPA will participate in the reviews and identify proposals of mutual interest and may provide co-funding for programs of high quality that meet their programatic and relevancy requirements.
URL : http://www.nsf.gov/cgi-bin/getpub?nsf0054
The Diagnostic Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.
If you wish to remain on the list, no action is necessary.
If you wish to be added to the list (or removed from it), please contact Johnnie Smith by return e-mail (firstname.lastname@example.org).
The staff of the Diagnostic Imaging Program places a high priority on communicating with and facilitating the work of researchers in the imaging community. We look forward to working with you.
Diagnostic Imaging Program Division of Cancer Treatment and Diagnosis, NCI Executive Plaza North, Room 800 6130 Executive Boulevard Rockville, MD 20892-7440 Tel: 301 496 9531 Fax: 301 480 5785